Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

导出原文传递

翻译打印收藏纠错

作者： Désirée,van der Heijde ^[1] ; In-Ho,Song ^[2] ; Aileen L,Pangan ^[2] ; Atul,Deodhar ^[3] ; Filip,van den Bosch ^[4] ; Walter P,Maksymowych ^[5] ; Tae-Hwan,Kim ^[6] ; Mitsumasa,Kishimoto ^[7] ; Andrea,Everding ^[8] ; Yunxia,Sui ^[2] ; Xin,Wang ^[2] ; Alvina D,Chu ^[2] ; Joachim,Sieper ^[9]

作者单位： Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands. Electronic address: mail@dvanderheijde.nl. ^[1] Immunology Clinical Development and Data and Statistical Sciences, AbbVie, North Chicago, IL, USA. ^[2] Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, USA. ^[3] Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium. ^[4] Department of Medicine, University of Alberta, Edmonton, AB, Canada. ^[5] Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. ^[6] Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan. ^[7] Hamburger Rheuma-Forschungszentrum, Hamburg, Germany. ^[8] Department of Gastroenterology, Infectious Diseases, and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany. ^[9]